Your tax-deductable gift will help us to be more effective in our mission to put an end to the worldwide epidemic of Vitamin D Deficiency.

Search

Vitamin D On The Web

See our Vitamin D News page for all the latest vitamin D headlines from around the globe.

Our Best Vitamin D Articles page for links to informative, less-mainstream articles on vitamin D and UV exposure.

Vitamin D Research

back to research menu

Pharmacology

Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol. 2008 Oct;62(5):787–97.
Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: Interactions with endothelial function and thioredoxin-interacting protein. Eur J Pharmacol. 2008 Aug 20;590(1–3):290–6.
Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol. 2008 Aug 15;76(4):531–42.
Novel vitamin D3 analogs, 1alpha, 25(OH)2D(3)-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts. Biochem Biophys Res Commun. 2008 Aug 1;372(3):434–9.
Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008 Aug;19(8):1509–19.
Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008 Aug;122(2):398–417. Review.
Comparison of Daily, Weekly, and Monthly Vitamin D3 in Ethanol Dosing Protocols for Two Months in Elderly Hip Fracture Patients. J Clin Endocrinol Metab. 2008 Jun 10.
Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatr Int. 2008 Jun;50(3):269–75.
Mineral metabolism and bone abnormalities in children with chronic renal failure. Rev Endocr Metab Disord. 2008 Jun;9(2):131–7. Review.
Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med. 2008 May 1.
Insulin resistance, renal injury, renal 1-alpha hydroxylase, and bone homeostasis in aged obese rats. Arch Med Res. 2008 May;39(4):380–7.
The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res. 2007 Sep–Oct;27(5A):3387–98.
What is new in vitamin D: 2006–2007. Curr Opin Rheumatol. 2007 Jul;19(4):383–8.
Phenobarbital suppresses vitamin D3 25-hydroxylase expression: a potential new mechanism for drug-induced osteomalacia. Biochem Biophys Res Commun. 2007 Jun 8;357(3):603–7.
Efficacy of daily and monthly high-dose calciferol in vitamin D-deficient nulliparous and lactating women. Am J Clin Nutr. 2007 Jun;85(6):1565–71.
Effect of 2-Methylene-19-nor-(20S)-1alpha-Hydroxy- Bishomopregnacalciferol (2MbisP), an Analog of Vitamin D, on Secondary Hyperparathyroidism. J Bone Miner Res. 2007 May;22(5):686–94.
Effects of atorvastatin on vitamin d levels in patients with acute ischemic heart disease. Am J Cardiol. 2007 Apr 1;99(7):903–5.
Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs. 2007 Apr;18(4):447–57.
Successful treatment of refractory warts with topical vitamin D(3) derivative (maxacalcitol, 1alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients. J Dermatol. 2007 Apr;34 (4):264–6.
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2007 Apr;59(5):581–7.
Vitamin D analogs for secondary hyperparathyroidism: What does the future hold? J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):578–83.
Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):689–93.
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int. 2007 Mar;27(5):425–34.
Difluoromethyl analogs of the natural hormone 1alpha,25-dihydroxyvitamin D(3): Design, synthesis, and preliminary biological evaluation. J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):213–21.
Structure-activity relationships of 19-norvitamin D analogs having a fluoroethylidene group at the C-2 position. Bioorg Med Chem. 2007 Feb 1;15(3):1475–82.
Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):134–44. Review.
New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) analogs strongly stimulate osteoclast formation both in vivo and in vitro. Bone. 2007 Feb;40(2):293–304.
ED-71, a novel vitamin D analog, promotes bone formation and angiogenesis and inhibits bone resorption after bone marrow ablation. Bone. 2007 Feb;40(2):281–292.
Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27(1):36–43.
The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics. Oncol Res. 2007;16(11):517–25.
Synthesis and evaluation of a 3-position diastereomer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D(3) (ED-71). Bioorg Med Chem. 2006 Dec 1;14(23):8050–6.
Comparison of the efficacy of calcipotriol and maxacalcitol in combination with narrow-band ultraviolet B therapy for the treatment of psoriasis vulgaris. Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):262–4.
Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol. 2006 Oct;21(10):1434–9.
Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS. 2006 Sep 11;20(14):1906–1907.
Antiepileptic drugs and bone metabolism. Nutr Metab (Lond). 2006 Sep 6;3(1):36
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord. 2006 Jul;21(7):924–9.
Synthesis of putative metabolites of 1alpha,25-dihydroxy-2beta-(3-hydroxy propoxy)vitamin D(3) (ED-71). Steroids. 2006 Jul;71(7):529–40.
Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther. 2006 Jul;318(1):90–8.
New 2-alkylidene 1alpha,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives. J Med Chem. 2006 May 18;49(10):2909–20.
Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 2006 May 15;106(10):2136–42.
Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women. Eur J Clin Nutr. 2006 May;60(5):681–7.
Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets. 2006 May;6(3):229–44. Review.
Practical synthesis and evaluation of the biological activities of 1alpha,25-dihydroxy vitamin D3 antagonists, 1alpha,25-dihydroxy vitamin D3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis. J Med Chem. 2006 Apr 20;49(8):2398–406.
Oral treatment with a vitamin D3 analogue (BXL628) has anti-inflammatory effects in rodent model of interstitial cystitis. BJU International Volume 97 Page 617—March 2006.
Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int. 2006 Mar;26(5):445–53.
Pharmacological treatment to augment hole board habituation in prenatal Vitamin D-deficient rats. Behav Brain Res. 2006 Jan 6;166(1):177–83.
Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med Chem. 2006 Jan;6(1):53–71. Review.
New horizons of ED-71 (vitamin D analog) Clin Calcium. 2006 Jan;16(1):131–5. In Japanese.
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8680–5.
Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. 2005 Nov 1;11(21):7794–9.
Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005 Nov;68(5):1973–81. Review.
Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):93–101. Review.
Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):111–20.
Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):173–7.
Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):137–43.
Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis. J Rheumatol Suppl. 2005 Sep;76:33–40.
Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J Rheumatol Suppl. 2005 Sep;76:26–32. Review.
High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol. 2005 Sep;174(3):888–92.
The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact. 2005 Jul–Sep;5(3):273–84. Review.
The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med. 2005 Aug 8–22;165(15):1737–42.
Antioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. Ann N Y Acad Sci. 2005 Aug;1053:319–29.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD000227. Review.
Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005 Mar;76(3):176–86.
Lack of effect of calcium intake on the 25-hydroxyvitamin d response to oral vitamin D3. J Clin Endocrinol Metab. 2005 Feb;90(2):707–11.
Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology. 2005 Feb;146(2):825–34.
Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease. Bone. 2005 Jan;36(1):61–8.
A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. JNNP 2005;76:1294–1296.
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 1;10(23):8018–27.
Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids. 2004 Sep;69(10):629–35.
Vitamin D2 Is Much Less Effective than Vitamin D3 in Humans Journal of Clinical Endocrinology & Metabolism 2004 Aug Vol. 89, No. 11 5387–5391.
1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J Steroid Biochem Mol Biol. 2004 May;89–90(1–5):567–70.
Zinc–induced apoptosis in substantia nigra of rat brain: neuroprotection by vitamin D3. Free Radic Biol Med. 2003 Jun 1;34(11):1416–25.
New vitamin D analogs. Kidney Int Suppl. 2003 Jun;(85):S83–7. Review.
Vitamin D receptor as a drug discovery target. Mini Rev Med Chem. 2003 May;3(3):193–204. Review.
Rationale for active vitamin D and analogs in the treatment of osteoporosis. J Cell Biochem. 2003 Feb 1;88(2):381–6. Review.
Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 2003;164:273–88.
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther. 2002 Dec;72(6):648–59.
New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002 Apr;13(3):100–5. Review.
Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism. Treat Endocrinol. 2002;1(5):313–27. Review.
Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002;17 Suppl 10:10–9. Review.
Vitamin D analogs for the treatment of secondary hyperparathyroidism. Blood Purif. 2002;20(1):109–12. Review.
Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34–40. Review.
Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol. 2001;41:421–42. Review.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2001;(1):CD000227. Review.
Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1alpha-hydroxyvitamin D(5). J Natl Cancer Inst. 2000 Nov 15;92(22):1836–40.
Prevention of vitamin D deficiency in adolescents and pre-adolescents. An interventional multicenter study on the biological effect of repeated doses of 100,000 IU of vitamin D3. Arch Pediatr. 2000 Feb;7(2):148–53. In French.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2000;(2):CD000227. Review.
Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int. 1999 Oct;65(4):337–40.
Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int. 1999 Oct;65(4):295–306. Review.
Vitamin D analogs: perspectives for treatment. Miner Electrolyte Metab. 1999 Jul–Dec;25(4–6):337–41. Review.
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998;8(3):222–30.
New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem. 1998 Nov 5;41(23):4662–74.
Evidence that vitamin D3 increases serum 25-hydroxy vitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998 Oct;68(4):854–8.
19-Nor-1-alpha-25-dihydroxy vitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998 Aug;9(8):1427–32.
Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem. 1997 Sep 1;66(3):413–25.
Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol. 1997 Aug;19(1):15–27.
Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. J Natl Cancer Inst. 1997 Feb 5;89(3):212–8.
Fortified milk and supplements of oral vitamin D. Comparison of the effect of two doses of vitamin D (500 and 1,000 UI/d) during the first trimester of life. Arch Pediatr. 1997 Feb;4(2):126–32. In French.
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis. CMAJ. 1996 Oct 1;155(7):955–61. Review.
Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol. 1996 Mar;7(3):488–96.
Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology. 1996 Feb;137(2):400–9.
Effect of three levels of vitamin D intake in preterm infants receiving high mineral-containing milk. J Pediatr Gastroenterol Nutr. 1995 Aug;21(2):182–9.
Vitamin D and pubertal maturation. Value and tolerance of vitamin D supplementation during the winter season. Arch Pediatr. 1995 Mar;2(3):221–6. In French.
Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan;136(1):20–6.
Immune modulation by vitamin D analogs in the prevention of autoimmune diseases. Verh K Acad Geneeskd Belg. 1995;57(5):371–85; discussion 385–7. In Dutch.
Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues. Cancer Res. 1993 Sep 1;53(17):3935–42.
Mineral and vitamin D adequacy in infants fed human milk or formula between 6 and 12 months of age. J Pediatr. 1990 Aug;117(2 Pt 2):S134–42. Review.
Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3. J Med Chem. 1990 Feb;33(2):480–90.
Effects of ergocalciferol supplementation on the concentration of vitamin D and its metabolites in human milk. J Nutr. 1989 Nov;119(11):1639–46.
The difference of biological activity among four diastereoisomers of 1 alpha,25-dihydroxycholecalciferol-26,23-lactone. J Steroid Biochem. 1986 Oct;25(4):505–10.
1,25-Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology. 1986 Apr;118(4):1433–9.
Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr. 1985 Oct;42(4):644–9.
Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1,24 Dihydroxycholecalciferol (1,24(OH)2D3). Endocrinol Jpn. 1985 Apr;32(2):305–15.
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3: a highly potent, long-lasting analog of 1,25-dihydroxyvitamin D3. Arch Biochem Biophys. 1984 Feb 15;229(1):348–54.
Serum dihydroxyvitamin D metabolite concentrations in patients on chronic anticonvulsant drug therapy: response to pharmacologic doses of vitamin D2. Metab Bone Dis Relat Res. 1983–1984;5(1):1–6.
Metabolism and binding properties of 24,24-difluoro-25-hydroxyvitamin D3. Arch Biochem Biophys. 1983 Sep;225(2):649–55.
Variation of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 levels in human plasma obtained from 758 Japanese healthy subjects. J Nutr Sci Vitaminol (Tokyo). 1983 Jun;29(3):271–81.
23-Keto-25-hydroxyvitamin D3: a vitamin D3 metabolite with high affinity for the 1,25-dihydroxyvitamin D specific cytosol receptor. Biochemistry. 1983 Jan 18;22(2):245–50.
Vitamin D metabolism in hypoparathyroidism. J Clin Endocrinol Metab. 1980 Sep;51(3):606–10.
Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3. J Clin Invest. 1976 Jul;58(1):61–70.
Vitamin D: the discovery of its metabolites and their therapeutic applications. Pediatrics. 1976 May;57(5):729–41. Review.
The kidney as an endocrine organ involved in the function of vitamin D. Am J Med. 1975 Jan;58(1):39–47. Review.
Gas chromatographic determination of vitamin D in cod liver oil, pharmaceuticals and veterinary preparations. Int J Vitam Nutr Res. 1973;43(3):271–82.

back to research menu

Unless otherwise expressly stated, all site content licensed under a Creative Commons License.

Vitamin D Newsletter

Search

Vitamin D On The Web

Pharmacology